A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors

Annals of Oncology

Volumn 15, Issue 8, 2004, Pages 1284-1294

  Mross, K ^a   Richly, H ^b   Schleucher, N ^b   Korfee, S ^b   Tewes, M ^a   Scheulen, M E ^b   Seeber, S ^b   Beinert, T ^c   Schweigert, M ^c   Sauer, N ^a   Unger, C ^a   Behringer, D ^d   Brendel, E ^e   Haase, C G ^e   Voliotis, D ^e   Strumberg, Dirk ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e BAYER PHARMA AG   (Germany)

Author keywords

Camptothecin glycoconjugate; Phase I; Topoisomerase I

Indexed keywords

AFELETECAN; ALKALINE PHOSPHATASE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CREATININE; GLYCOCONJUGATE; METOCLOPRAMIDE; ONDANSETRON; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 4444337298     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh313     Document Type: Article

References (36)

1. Ulukan H, Swaan PW. Camptothecins: a review of their chemotherapeutic potential. Drugs 2002; 62: 2039-2057.
2. Kim DK, Lee N. Recent advances in topoisomerase I-targeting agents, camptothecin analogues. Mini Rev Med Chem 2002; 2: 611-619.
3. Jung LL, Zamboni WC. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it? Drug Resist Updat 2001; 4: 152-167.
4. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
5. Wang X, Zhou X, Hecht SM. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex. Biochemistry 1999; 38: 4374-4381.
6. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34: 755-760.
7. Bailly C. Topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 2000; 7: 39-58.
8. Goldwasser F, Bae I, Valenti M et al. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen. Cancer Res 1995; 55: 2116-2121.
9. Gradzka I, Szumiel I. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines. Cell Biochem Funct 1996; 14: 163-171.
10. Liu LF, Duann P, Lin CT et al. Mechanism of action of camptothecin. Ann N Y Acad Sci 1996; 803: 44-49.
11. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 83-105.
12. Takimoto CH, Arbuck S. Topoisomerase I targeting agents: the camptothecins. In Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice, 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins 2001; 538.
13. Ryan AJ, Squires S, Strutt HL, Johnson RT. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucleic Acids Res 1991; 19: 3295-3300.
14. Strumberg D, Pilon AA, Smith M et al. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 2000; 20: 3977-3987.
15. Tsao YP, Russo A, Nyamuswa G et al. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 1993; 53: 5908-5914.
16. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-5082.
17. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997; 272: 24159-24164.
18. Goldwasser F, Shimizu T, Jackman J et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996; 56: 4430-4437.
19. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56: 95-101.
20. Muggia FM, Creaven PJ, Hansen HH et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 1972; 56: 515-521.
21. Takimoto CH, Arbuck SG. Clinical status and optimal use of topotecan. Oncology (Huntingt) 1997; 11: 1635-1646. (Discussion 1649-1651, 1655-1657).
22. FDA. FDA approves irinotecan as first-line therapy for colorectal cancer. Oncology (Huntingt) 2000; 14: 652-654.
23. Burke TG, Munshi CB, Mi Z, Jiang Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J Pharm Sci 1995; 84: 518-519.
24. Burke TG. Chemistry of the camptothecins in the bloodstream. Drug stabilization and optimization of activity. In Pantazis P, Giovanella BC, Rothenberg M (eds): The Camptothecins: from Discovery to the Patient. New York: New York Academy of Sciences 1996; 29-31.
25. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-684.
26. Liehr JG, Ahmed AE, Giovanella BC. Pharmacokinetics of camptothecins administered orally. In Pantazis P, Giovanella BC, Rothenberg M (eds): The Camptothecins: from Discovery to the Patient. New York: New York Academy of Sciences 1996; 157-163.
27. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst 1992; 9: 135-187.
28. Lerchen HG, Baumgarten J, von dem Bruch K et al. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 2001; 44: 4186-4195.
29. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Offset Publication No.48, Geneva, Switzerland: WHO, 1979.
30. Kawato Y, Furuta T, Aonuma M et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-198.
31. Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 1501-1518.
32. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996; 23 (1 Suppl 3): 34-41.
33. Rowinsky EK, Rizzo J, Ochoa L et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-h infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 2003; 21: 148-157.
34. Zhao H, Lee C, Choe YH. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J Org Chem 2000; 65: 4601-4606.
35. Conover CD, Greenwald RB, Pendi A. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin after its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol 1998; 42: 407-414.
36. Schoemaker NE, van Kesteren C, Rosing H et al. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br J Cancer 2002; 87: 608-614.